Release The Power Of Precise Proteomics
Accelerating proteomics-driven precision medicine
Precision Biomarker Laboratories, a commercial contract research organization (CRO) wholly owned by Cedars-Sinai Medical Center, provides complete proteomics solutions across biomarker discovery, validation and CAP/CLIA-certified laboratory testing capabilities. Our customized workflows allow for the quick translation from protein discovery to clinically validated targeted panels.
Innovative and Integrated Solutions

The proteome is a dynamic indicator of health
Unlike the genome, the proteome changes over time and throughout the life builds up a tremendous complexity. From around 22000 human genes, more than a million proteoforms are translated, forming a dynamic pool of indicators for health and illness.
The proteome not only serves as a signature of current physiological status in response to multiple change triggers and perturbations, but also offers relevant insights into targets for therapeutic intervention.
Proteomics provides valuable data:
Analyzing the proteome provides multiple layers of information about proteins like expression, function, structure, subcellular location, post-translational modifications (PTMs) and protein-protein interactions.
Combining layers of proteome knowledge reveal insights into:
- Impact of disease triggers
- Mechanism of a disease
- Treatment opportunities and intervention

Accelerate your breakthrough
drugs and diagnostics
Drug Discovery
Our integrated proteomics workflows are designed to accelerate the drug discovery process and maximize the development success.
Pre-Clinical Studies
Robust workflows are available across all types of biological samples, including blood, plasma, cells, tissue, and other physiological fluids.
Diagnostics
Precision Biomarker Laboratories delivers quantitative proteomics data with high-precision, depth, and reproducibility.